REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

REGENXBIO Inc.NASDAQ: RGNX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 88.3% from a year ago

Cash & equivalents stood at $15.23M at the end of Q1 FY2026, down 88.3% from a year earlier and down 55.8% from the prior quarter. Over 3 fiscal years it compounded at -29.2% a year.

Context

  • Cash & equivalents amounted to 4.5% of total assets at the end of Q1 FY2026, down 22.0 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -88.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.23M-55.8% QoQ
Last fiscal yearDec 2025
$34.47M-40.1% YoY
Year agoMar 2025
$130.1M-88.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-88.3%——
1 year-40.1%——
3-year CAGR-29.2%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
34.47M USD
Year-over-year change
-40.1%
4-year CAGR
-43.8%

Cash & Equivalents vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's Mar 2026 cash & equivalents of $15.23M is the lowest of the 10 companies compared; the peer median is $71.54M.
  • Its year-over-year change of -88.3% is the lowest of 10, against a peer median of -0.4%.
  • Cash & equivalents amounts to 4.5% of total assets for RGNX, versus a peer median of 19.7%.
RGNX Competitors Peer median
Cash & Equivalents for RGNX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SLDBSolid Biosciences Inc.Mar 2026$297.74M +41.4%-27.2%70.4%
QUREuniQure N.V.Mar 2026$139.99M -35.6%-29.4%18.0%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$72.49M -45.7%+4.8%14.1%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$71.77M +148.2%-6.6%28.7%
MGTXMeiraGTx Holdings plcMar 2026$71.54M +7.5%-17.1%29.2%
RCKTRocket Pharmaceuticals, Inc.Mar 2026$49.61M -0.4%-18.0%17.4%
VYGRVoyager Therapeutics, Inc.Mar 2026$43.31M -42.1%-12.9%19.7%
OCGNOcugen, Inc.Mar 2026$31.86M -15.7%-37.9%56.0%
PGENPrecigen, Inc.Jun 2026$16.33M +18.7%+83.9%9.6%
RGNXREGENXBIO Inc.Mar 2026$15.23M -88.3%-29.2%4.5%
Peer median (excluding RGNX) $71.54M-0.4%-17.1%19.7%

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents345.21M96.95M34.52M57.53M34.47M
Short-term Investments112.23M267.69M240.74M177.16M195.6M
Net Receivables32.44M30.29M26.34M21.57M27.38M
Inventory00000
Other Current Assets10.2M7.14M18.85M12.68M11.9M
Total Current Assets518.83M415.98M334.97M278M281.28M
Property, Plant & Equipment (Net)192.45M206.8M192.59M171.31M152.01M
Goodwill00000
Intangible Assets00000
Long-term Investments391.91M200.56M38.87M10.18M15.13M
Tax Assets00000
Other Non-current Assets10.72M9.93M7.54M6.5M4.61M
Total Non-current Assets595.08M417.29M239M187.99M171.75M
Total Assets1.11B833.27M573.97M465.99M453.03M
Account Payables11.39M27.21M22.79M22.8M21.36M
Short-term Debt000047.9M
Tax Payables11.33M0000
Deferred Revenue3.33M1.83M148K115K10.45M
Other Current Liabilities57.74M66.67M86.04M51.92M20.97M
Total Current Liabilities130.47M130.43M130.27M103.19M118.1M
Long-term Debt0000147.41M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000018.94M
Other Non-current Liabilities134.21M97.84M49.73M29.01M638K
Total Non-current Liabilities219.13M186.64M131.96M103.14M232.2M
Total Liabilities349.61M317.07M262.23M206.34M350.3M
Common Stock4K4K4K5K5K
Retained Earnings(161.23M)(441.55M)(705.05M)(932.15M)(1.13B)
Accumulated OCI(2.57M)(15.4M)(4.43M)(741K)(687K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity764.3M516.2M311.74M259.65M102.73M
Total Debt86.68M94.8M89.29M82.03M260.52M
Net Debt(258.53M)(2.15M)54.77M24.51M226.05M

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.